BCMA CAR-NK
/ Hrain Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 21, 2023
To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
(clinicaltrials.gov)
- P1 | N=18 | Recruiting | Sponsor: Hrain Biotechnology Co., Ltd.
New P1 trial • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology • GZMB • IL15 • IL6
1 to 1
Of
1
Go to page
1